2020 HIGHLIGHTS Investments PROTEOR an innovative tech-enabled offering that allows its Investment date: December 2020 customers to rapidly reduce costs, minimize their Sector: External prosthetic medical devices risk of non-compliance with software publishers Country: France and consistently optimize the management of their — software and cloud assets. Elée serves more than Proteor is an independent family business, founded100 clients, including the French State and over half over 100 years ago and headquartered in Dijon,of the CAC40 companies. France. Proteor operates in the orthotics and prosthetics market with three main business areas: software, components and custom orthopedic devices. Thanks to continuous investments in innovation, numerous medicaland scientific partnerships,and daily cooperation with orthopedists, Proteor benefits from recognized expertise in the orthopedic sector. H2 PHARMA Investment date: October 2020 Sector: Non-sterile liquid pharmaceutical specialties Country: France — ELÉE H2 Pharma is a privileged partner of all pharma- Investment date: November 2020 ceuticalcompanies for theirgeneric or OTC Sector: Software asset management products.Today considered as the reference in Country: France the segment of non-sterile liquid pharmaceutical — specialties (mouthwash, syrup, oral solutions, etc.), Elée is one of the pioneers and the leading inde-H2 Pharma has holistic control of the entire value pendent tech-enabled managed services providerchain. Its industrial practices, its innovation capacity of software asset management and cloud computingin pharmaceutical flow and its cutting-edge technol- solutions in France. The company has developedogy enable H2 Pharma to differentiate itself. 76 INVESTMENT ACTIVITIES